These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 27053232)

  • 1. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?
    Byrne CD; Targher G
    Diabetologia; 2016 Jun; 59(6):1141-4. PubMed ID: 27053232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?
    Blond E; Disse E; Cuerq C; Drai J; Valette PJ; Laville M; Thivolet C; Simon C; Caussy C
    Diabetologia; 2017 Jul; 60(7):1218-1222. PubMed ID: 28352941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Non-alcoholic fatty liver disease - a summary and update based on the EASL-EASD-EASO Clinical Practice Guidelines of 2016].
    Nádasdi Á; Somogyi A; Igaz P; Firneisz G
    Orv Hetil; 2018 Nov; 159(45):1815-1830. PubMed ID: 30415572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.
    Sberna AL; Bouillet B; Rouland A; Brindisi MC; Nguyen A; Mouillot T; Duvillard L; Denimal D; Loffroy R; Vergès B; Hillon P; Petit JM
    Diabet Med; 2018 Mar; 35(3):368-375. PubMed ID: 29247558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.
    Petroff D; Blüher M; Wiegand J
    Dig Liver Dis; 2018 Jul; 50(7):731-733. PubMed ID: 29699861
    [No Abstract]   [Full Text] [Related]  

  • 8. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
    ; ;
    Diabetologia; 2016 Jun; 59(6):1121-40. PubMed ID: 27053230
    [No Abstract]   [Full Text] [Related]  

  • 9. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
    ; ;
    J Hepatol; 2016 Jun; 64(6):1388-402. PubMed ID: 27062661
    [No Abstract]   [Full Text] [Related]  

  • 10. Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016.
    Ciardullo S; Sala I; Perseghin G
    Diabetes Res Clin Pract; 2020 Sep; 167():108358. PubMed ID: 32745698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms.
    Zelber-Sagi S; Salomone F; Mlynarsky L
    Liver Int; 2017 Jul; 37(7):936-949. PubMed ID: 28371239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lifestyle interventions for non-alcoholic fatty liver disease.
    Ahmed IA; Mikail MA; Mustafa MR; Ibrahim M; Othman R
    Saudi J Biol Sci; 2019 Nov; 26(7):1519-1524. PubMed ID: 31762620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions.
    Anstee QM; Hallsworth K; Lynch N; Hauvespre A; Mansour E; Kozma S; Marino JP; Bottomley J; Piercy J; Higgins V
    JHEP Rep; 2022 Jan; 4(1):100411. PubMed ID: 34977520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: guidelines, clinical reality and health economic aspects.
    Toplak H; Stauber R; Sourij H
    Diabetologia; 2016 Jun; 59(6):1148-9. PubMed ID: 27053233
    [No Abstract]   [Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease: A patient guideline.
    Francque SM; Marchesini G; Kautz A; Walmsley M; Dorner R; Lazarus JV; Zelber-Sagi S; Hallsworth K; Busetto L; Frühbeck G; Dicker D; Woodward E; Korenjak M; Willemse J; Koek GH; Vinker S; Ungan M; Mendive JM; Lionis C
    JHEP Rep; 2021 Oct; 3(5):100322. PubMed ID: 34693236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination.
    Blank V; Petroff D; Beer S; Böhlig A; Heni M; Berg T; Bausback Y; Dietrich A; Tönjes A; Hollenbach M; Blüher M; Keim V; Wiegand J; Karlas T
    Sci Rep; 2020 Oct; 10(1):18345. PubMed ID: 33110165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of non-alcoholic fatty liver disease (NAFLD).
    Yki-Järvinen H
    Diabetologia; 2016 Jun; 59(6):1104-11. PubMed ID: 27091184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
    Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
    Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?
    Lazarus JV; Palayew A; Carrieri P; Ekstedt M; Marchesini G; Novak K; Ratziu V; Romero-Gómez M; Tacke F; Zelber-Sagi S; Cortez-Pinto H; Anstee QM
    JHEP Rep; 2021 Apr; 3(2):100234. PubMed ID: 33733078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.